Catecholamines and Affective Illness: Studies with L-DOPA and Alpha-Methyl-Para-Tyrosine

  • Elliot S. Gershon
  • William E. BunneyJr.
  • Frederick K. Goodwin
  • Dennis L. Murphy
  • David L. Dunner
  • George M. Henry
Part of the Advances in Behavioral Biology book series (ABBI, volume 1)


In this paper we will review previous data and present new data on the clinical effects of L-dihydroxyphenylalanine (L-DOPA) and alpha-methyl-para- tyrosine (α-MPT) in the affective disorders and on the biochemical pharmacology of these agents in man and in the laboratory animal. These studies were prompted by the catecholamine hypothesis, which remains of central importance in current research in the affective disorders (Bunney and Davis 1965; Schildkraut 1965). This hypothesis proposes that some, if not all, depressions are associated with a deficiency of catecholamines at functionally important adrenergic sites in brain, and that mania may be associated with an excess of these amines (Schildkraut 1965). Pharmacologic agents that cause an increase in active catecholamines released by appropriate neurons should be associated with alleviation of depression or production of mania, and pharmacologic agents that cause a decrease in the amount of catecholamines available to the receptor should be associated with worsening of depression or improvement of mania.


Tyrosine Hydroxylase Depressed Patient Bipolar Patient Homovanillic Acid Affective Illness 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Angst, J. 1966. Zur Atiologie und Nosologie endogener depressiver Psychosen. Monographien aus dem Gesamtgebiete der Neurologie und Psychiatrie, No. 112. Berlin: Springer-Verlag.Google Scholar
  2. Anton, A. H., and Sayne, D. F. 1962. A study of the factors affecting the aluminum oxidethihydroxyindole procedure for the analysis of catecholamines. J., Pharmacol. Exp. Ther. 138:360.Google Scholar
  3. Ashcroft, G. W.; Crawford, T. B. B.; Eccleston, D.; Sharman, D. F.; MacDougall, E. J.; Stanton, J. B.; and Binns, J. K. 1966. 5-Hydroxy-indole compounds in the cerebrospinal fluid of patients with psychiatric or neurological diseases. Lancet 2:1049.PubMedCrossRefGoogle Scholar
  4. Ashcroft, G. W., and Sharman, D. F. 1960. 5-Hydroxyindoles in human cerebrospinal fluids. Nature 186:1050.PubMedCrossRefGoogle Scholar
  5. Ashcroft, G., and Sharman, D. F. 1962. Changes in the concentration of 5-OR indolyl compounds in cerebrospinal fluid and caudate nucleus. Brit. J. Pharmacol. 19:153.PubMedGoogle Scholar
  6. Bertler, A.; Falck, B.; Owman, C.; and Rosengreen, E. 1966. The localization of monoaminergic blood-brain barrier mechanisms. Pharmacol. Rev. 18:369.PubMedGoogle Scholar
  7. Bouhon, C. 1970. Pharmacological and immunological studies of cate-chol-O-methy1transferase. Seminar given at Laboratory of Clinical Science. National Institute of Mental Health.Google Scholar
  8. Bowers, M. B., Jr., and Gerbode, F. 1968. CSF 5HIAA: Effects of probenecid and parachlorophenylalanine. Life Sci. 7:773.CrossRefGoogle Scholar
  9. Brodie, H. K. H.; Murphy, D. L.; Goodwin, F. K.; and Bunney, W. E., Jr. Catecholamines and mania: the effect of alpha-methyl-para-tyrosine on manic behavior and catecholamine metabolism. Clin. Pharmacol. Ther., in press.Google Scholar
  10. Bunney, W. E., Jr.; Brodie, H. K. H.; Murphy, D. L.; and Goodwin, F. K. 1971. Studies of alpha-methyl-para-tyrosine, L-DOPA, and L-tryptophan in depression and mania. Amer. J. Psychiat. 127:872.PubMedGoogle Scholar
  11. Bunney, W. E., Jr., and Davis, J. M. 1965. Norepinephrine in depressive reactions. Arch. Gen. Psychiat. 13:483.PubMedCrossRefGoogle Scholar
  12. Bunney, W. E., Jr., and Hamburg, D. A. 1963. Methods for reliable longitudinal observation of behavior. Arch. Gen. Psychiat. 9:280.PubMedCrossRefGoogle Scholar
  13. Bunney, W. E., Jr.; Janowsky, D. S.; Goodwin, F. K.; Davis, J. M.; Brodie, H. K. H.; Murphy, D. L.; and Chase, T. N. 1969. Effect of L-DOPA on depression. Lancet 1:885.PubMedCrossRefGoogle Scholar
  14. Bunney, W. E., Jr.; Murphy, D. L.; Brodie, H. K. H.; and Goodwin, F. K. 1970. L-DOPA in depressed patients. Lancet 1:352.PubMedCrossRefGoogle Scholar
  15. Butcher, L. L., and Engel, J. 1969. Behavioral and biochemical effects of L-DOPA after peripheral decarboxylase inhibition. Brain Res. 15:233.PubMedCrossRefGoogle Scholar
  16. Calne, D. B.; Stern, G. M.; Laurence, D. R.; Sharkey, J.; and Armi-tage, P. 1969. L-DOPA in postencephalitic parkinsonism. Lancet 1:744.PubMedCrossRefGoogle Scholar
  17. Chalmers, J. P.; Baldessarini, R. J.; and Wurtman, R. J. Effects of L-DOPA on brain norepinephrine metabolism. To be published.Google Scholar
  18. Coppen, A.; Prange, A. J.; Whybrow, P. C.; Noguera, R.; and Paez, J. M. 1969. Methysergide in mania: a controlled trial. Lancet 2:338.PubMedCrossRefGoogle Scholar
  19. Dencker, S. J.; Malm, U.; Roos, B. E.; and Werdinius, B. 1966. Acid monoamine metabolites of cerebrospinal fluid in mental depression and mania. J. Neurochem. 13:1545.PubMedCrossRefGoogle Scholar
  20. Dunner, D. L.; Gershon, E. S.; and Goodwin, F. K. 1970. Heritable factors in the severity of affective illness. Presented to annual meeting American Psychiatric Association, San Francisco.Google Scholar
  21. Engelman, K; Horwitz, D.; Jequier, E,; and Sjoerdsma, A. 1968. Biochemical and pharmacologic effects of α-methyltyrosine in man. J. Clin. Invest. 47:577.PubMedCrossRefGoogle Scholar
  22. Everett, G. M., and Borcherding, J. W. 1970. L-DOPA: Effect on concentrations of dopamine, norepinephrine and serotonin in brains of mice. Science 168:849.PubMedCrossRefGoogle Scholar
  23. Gerbode, F., and Bowers, W. 1960. Measurement of acid monoamine metabolites in human and animal cerebrospinal fluid. J. Neurochem. 15:1053.CrossRefGoogle Scholar
  24. Gershon, E. S.; Goodwin, F. K; and Gold, P. 1970. Effect of L-tyro-sine and L-DOPA on norepinephrine turnover in rat brain in vivo. Pharmacologist 12:268.Google Scholar
  25. Goodwin-Austen, R. B.; Tomlinson, E. B.; Frears, C. C.; and Kok, H.W.L. 1969. Effects of L-DOPA in Parkinson’s disease. Lancet 2:165.CrossRefGoogle Scholar
  26. Goodwin, F. K.; Brodie, H. K. H.; Murphy, D. L.; and Bunney, W. E., Jr. 1970a. Administration of a peripheral decarboxylase inhibitor with L-DOPA to depressed patients. Lancet 1:908.PubMedCrossRefGoogle Scholar
  27. Goodwin, F. K.; Dunner, D. L.; and Gershon, E. S. Turnover estimates of brain amines in depressed patients treated with L-DOPA. In preparation, 1971.Google Scholar
  28. Goodwin, F. K.; Murphy, D. L.; Brodie, H. K. H.; and Bunney, W. E., Jr. 1970b. L-DOPA, catecholamines, and behavior: a clinical and biochemical study in depressed patients. Biol. Psychiat. 2:341.PubMedGoogle Scholar
  29. Goodwin, F. K.; Murphy, D. L.; Dunner, D. L.; Bunney, W. E., Jr. 1971. Lithium response in unipolar vs. bipolar depression. Presentation to annual meeting, American Psychiatric Association, Washington, D. C.Google Scholar
  30. Greenspan, K.; Schildkraut, J. J.; Gordon, E. K.; Baer, L.; Aronoff, M. S.; and Durell, J. 1970. Catecholamine metabolism in affective disorders — III: MHPG and other catecholamine metabolites in patients treated with lithium carbonate. J. Psychiat. Res. 7:171.PubMedCrossRefGoogle Scholar
  31. Guldberg, H. C.; Ashcroft, G. W.; and Crawford, T. B. B. 1966. Concentrations of 5-hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid of the dog before and during treatment with probenecid. Life Sci. 5:1571.PubMedCrossRefGoogle Scholar
  32. Ingvarsson, V. C. G. 1965. Orientierende klinische Versuche zur Wirkung des Dioxyphenylalanins (L-DOPA) bei endogener Depression. Arz-neimittelforschung 15:849.Google Scholar
  33. Janowsky, D. S.; Leff, M.; and Epstein, R. S. 1970. Playing the manic game. Arch. Gen. Psychiat. 22:252.PubMedCrossRefGoogle Scholar
  34. Johnson, G. A.; Kim, E. G.; and Boukma, S. J. 1968. Mechanism of NE depletion by 5-hydroxytryptophan. Proc. Soc. Exp. Biol. Med. (Pharmacol.) 128:509.Google Scholar
  35. Klerman, G. L.; Schildkraut, J. J.; Hasenbush, L. L.; Greenblatt, M.; and Friend, D. G. 1963. Clinical experience with dihydroxyphenyla-lanine (Dopa) in depression. J. Psychiat. Res. 1:289.CrossRefGoogle Scholar
  36. Kopin, I. J.; Breese, G. R.; Krauss, R. R.; and Weise, V. K. 1968. Selective release of newly synthesized norepinephrine from the cat spleen during sympathetic nerve stimulation. J. Pharmaccol. Exp. Ther. 161:271.Google Scholar
  37. Kopin, I. J., and Gordon, E. Unpublished communication.Google Scholar
  38. Kuruma, I.; Bartholini, G.; and Pletscher, A. 1970. L-DOPA induced accumulation of 3-O-methyl-DOPA in brain and heart. Europ. J. Pharmacol. 10:189.CrossRefGoogle Scholar
  39. Leonhard, K.; Korff, I.; and Shulz, H. 1962. Die Temperamente in den Familien der monopolaren und bipolaren phasischen Psychosen. Psychiat. Neurol. 143:416.CrossRefGoogle Scholar
  40. Maas, J. W.; Fawcett, J.; and Dekirmenjian, H. 1968. 3-Methoxy-4-hydroxy phenylglycol (MHPG) excretion in depressive states. Arch. Gen. Psychiat. 18:129.CrossRefGoogle Scholar
  41. Maas, J. W.; Fawcett, J.; Dekirmenjian, H.; and Landis, D. H. Cate-cholamine metabolism and depressive states: current studies, in NIMH workshop, recent advances in the psychobiology of depressive illnesses, held in Williamsburg, Virginia, April 1969. U. S. Govt. Printing Office, in press.Google Scholar
  42. Mannarino, E.; Kirshner, N.; and Nashold, B. S. 1963. The metabolism of [C14] noradrenaline by cat brain in vivo. J. Neurochem. 10:373.CrossRefGoogle Scholar
  43. Matussek, N.; Pohlmeier, H.; and Ruther, E. 1966. Die Wirkung von Dopa auf gehemmte Depressionen. Klin. Wschr. 44:727.PubMedCrossRefGoogle Scholar
  44. McDowell, F.; Lee, J. E.; Swift, T.; Sweet, R. D.; Ogsbury, J. S.; and Kessler, J. T. 1970. Treatment of Parkinson’s syndrome with 1-dihydroxyphenylalanine (levodopa). Ann. Inter. Med. 72:29.Google Scholar
  45. McNemar, Q. 1969. Psychological Statistics. 4th Ed. New York: Wiley.Google Scholar
  46. Murphy, D. L.; Brodie, H. K. H.; Goodwin, F. K.; and Bunney, W. E., Jr. 1971. Regular induction of hypomania by L-DOPA in “bipolar” manic-depressive patients. Nature 229:135.PubMedCrossRefGoogle Scholar
  47. Neff, N. H.; Tozer, T. N.; and Brodie, B. B. 1967. Application of steady-state kinetics to studies of the transfer of 5-hydroxyindole-acetic acid from brain to plasma. J. Pharmacol. Exp. Ther. 158:214.Google Scholar
  48. Ng, K. Y.; Chase, T. N.; Colburn, R. W.; and Kopin, I. J. 1971. L-DOPA induced release of cerebral monoamines. Science 170:76.CrossRefGoogle Scholar
  49. O’Brien, C. P.; DiGiacomo, J. N.; Fahn, S.; and Schwarz, G. A. 1971. Mental effects of high-dosage levodopa. Arch. Gen. Psychiat. 24:61.PubMedCrossRefGoogle Scholar
  50. Pare, C. M. B., and Sandier, M. J. 1959. A clinical and biochemical study of a trial of iproniazid in the treatment of depression. J. Neurol. Neurosurg. Psychiat. 22:247.PubMedCrossRefGoogle Scholar
  51. Perris, C. 1966. A study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses. Acta Psychiat. Scand. 42:suppl. 194.Google Scholar
  52. Roos, B. E.; and Sjostrum, R. 1969. 5-Hydroxyindoleacetic acid (and homovanillic acid) levels in the cerebrospinal fluid after probene-cid application in patients with manic-depressive psychosis. Phar-macologia Clinica 1:153.CrossRefGoogle Scholar
  53. Rose, C. M.; Chou, C.; and Wurtman, R. J. 1970. The metabolism of 14C-DOPA in the whole mouse. Fed. Proc. 29:511.Google Scholar
  54. Sato, T. L, 1965. The quantitative determination of 3-methoxy-4-hydroxyphenylacetic acid (homovanillic acid) in urine. J. Lab. Clin. Med. 66:517.PubMedGoogle Scholar
  55. Schanberg, S. M.; Schildkraut, J. J.; and Kopin, I. J. 1967. Nor-metanephrine H3 (NMN-H3) turnover and conversion to a deaminated conjugate as a major metabolite in rat brain. Fed. Proc. 26:464.Google Scholar
  56. Schildkraut, J. J. 1965. The catecholamine hypothesis of affective disorders: A review of supporting evidence. Amer. J. Psychiat. 122:509.PubMedGoogle Scholar
  57. Sjoerdsma, A.; Engelman, K.; Spector, S.; and Udenfriend, S. 1965. Inhibition of catecholamine synthesis in man with alphamethyltyro-sine, an inhibitor of tyrosine hydroxylase. Lancet 2:1092.PubMedCrossRefGoogle Scholar
  58. Sourkes, T. L., and Murphy, G. F. 1961. Determination of catechol-amines and catecholamino acids by differential spectrophotofluori-metry. Meth. Med. Res. 9:147.PubMedGoogle Scholar
  59. Spector, S.; Sjoerdsma, A.; and Udenfriend, S. 1965. Blockade of endogenous norepinephrine synthesis by α-methyl-tyrosine, an inhibitor of tyrosine hydroxylase. J. Pharmacol. Exp. Ther. 147:86.PubMedGoogle Scholar
  60. Turner, W., and Merlis, S, 1964. A clinical trial of pargyline and Dopa in psychotic subjects. Dis. Nerv. Syst. 25:538.PubMedGoogle Scholar
  61. Udenfriend, S. 1966. Tyrosine hydroxylase. Pharmacol. Rev. 18:43.PubMedGoogle Scholar
  62. Udenfriend, S.; Titus, E.; and Weissbach, H. 1955. The identification of 5-hydroxy-3-indoleacetic acid in normal urine and a method for its assay. J. Biol. Chem. 216:499.PubMedGoogle Scholar
  63. Udenfriend, S.; Zaltzman-Nirenberg, P.; Gordon, R.; and Spector, S. 1966. Evaluation of the biochemical effects produced in vivo by inhibitors of the three enzymes involved in norepinephrine biosynthesis. Molec. Pharmacol. 2:95.Google Scholar
  64. van Praag, H. M.; Korff, J.; and Puite, J. 1970. 5-Hydroxyindole-acetic acid levels in the cerebrospinal fluid of depressive patients treated with probenecid. Nature 225:1259.PubMedCrossRefGoogle Scholar
  65. Weil-Malberbe, H. The estimation of total (free and conjugated) cate-cholamines and some catecholamine metabolites in human urine. In Me-thods of Biochemical Analysis. D. Glick (ed.). 16:293. Intersci-ence Publishers, in press.Google Scholar
  66. Werdinius, B. 1966. Effect of probenecid on the level of homovanil-lic acid in the corpus striatum. J. Pharmacol. Exp. Ther. 18:546.Google Scholar
  67. Werdinius, B. 1967. Effect of probenecid on the levels of monoamine metabolites in the rat brain. Acta Pharmacol. 25:18.CrossRefGoogle Scholar
  68. Wilk, S.; Gitlow, S. E.; Clarke, D. D.; and Paley, D. H. 1967. Determination of urinary 3-methoxy-4-hydroxy-phenylethylene glycol by gas-liquid chromatography and electron capture detection. Clin. Chim. Acta 16:403.PubMedCrossRefGoogle Scholar
  69. Winokur, G.; Clayton, P. J.; and Reich, T. 1969. Manic-Depressive Illness. St. Louis: C. V. Mosby.Google Scholar
  70. Wurtman, R. J.; Rose, C. M.; Matthysse, S.; Stephenson, J.; and Bal-dessarini, R. 1970. L-Dihydroxyphenylalanine: effect on S-adeno-sylmethionine in brain. Science 169:395.PubMedCrossRefGoogle Scholar
  71. Yahr, M. D.; Duvoisin, R. C.; Schear, J. J.; Barrett, R. E.; and Hoehn, M. M. 1969. Treatment of Parkinsonism with levodopa. Arch. Neurol. 21:343.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1971

Authors and Affiliations

  • Elliot S. Gershon
    • 1
  • William E. BunneyJr.
    • 1
  • Frederick K. Goodwin
    • 1
  • Dennis L. Murphy
    • 1
  • David L. Dunner
    • 1
  • George M. Henry
    • 1
  1. 1.Section on Psychiatry, Laboratory of Clinical ScienceNational Institute of Mental HealthBethesdaUSA

Personalised recommendations